-
Subject Areas on Research
-
"Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke.
-
A Bigger Look Into the "Therapeutic Window" of Platelet Reactivity to Adenosine Diphosphate.
-
A meta-analysis and genome-wide association study of platelet count and mean platelet volume in african americans.
-
A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity.
-
A radioreceptor assay for quantitating plasma factor VIII/von Willebrand's protein.
-
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
-
A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function.
-
Abciximab readministration: results of the ReoPro Readministration Registry.
-
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
-
Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?
-
Actions of thrombin in the interstitium.
-
Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation.
-
An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation.
-
An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial.
-
Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy.
-
Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.
-
Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus.
-
Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone.
-
Antiplatelet resistance--fact or myth?
-
Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.
-
Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study).
-
Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function.
-
Aspirin resistance and a single gene.
-
Aspirin resistance.
-
Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
-
Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center.
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
-
Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease.
-
Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction.
-
Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
-
Bolus magnesium infusion in humans is associated with predominantly unfavourable changes in platelet aggregation and certain haemostatic factors.
-
CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.
-
Carbohydrate on human factor VIII/von Willebrand factor. Impairment of function by removal of specific galactose residues.
-
Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo.
-
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.
-
Changes in the haemostatic profile during magnesium deficiency in swine.
-
Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements.
-
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
-
Clinical utility of available methods for determining platelet function.
-
Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial).
-
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists.
-
Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
-
Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations.
-
Clopidogrel dosing in overweight patients: does one size fit all?
-
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
-
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
-
Clopidogrel resistance?
-
Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.
-
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.
-
Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.
-
Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery.
-
Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review.
-
Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine.
-
Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor?
-
Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study.
-
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
-
Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study.
-
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
-
Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.
-
Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation.
-
Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting.
-
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
-
Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad.
-
Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.
-
Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials.
-
Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
-
Differential effects of cytochalasin B on platelet release, aggregation and contractility: evidence against a contractile mechanism for the release of platelet granular contents.
-
Do NSAIDs interfere with the cardioprotective effects of aspirin?
-
Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial.
-
Drug insight: Clopidogrel nonresponsiveness.
-
Drug interactions complicate antiplatelet therapy.
-
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
-
Durability of platelet inhibition by clopidogrel.
-
Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl).
-
Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study.
-
Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study.
-
Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study.
-
Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy).
-
Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation.
-
Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting.
-
Effect of magnesium sulphate infusion on ex vivo platelet aggregation in swine.
-
Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease.
-
Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.
-
Effects of 9,12,15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on the platelet aggregation.
-
Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
-
Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion.
-
Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
-
Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
-
Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits.
-
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
-
Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study.
-
Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function.
-
Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.
-
Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.
-
Ether lipid metabolism by AADACL1 regulates platelet function and thrombosis.
-
Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
-
Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?
-
Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.
-
Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2.
-
Facilitated versus primary PCI for acute myocardial infarction.
-
Factor VIII/von Willebrand protein. Modification of its carbohydrate causes reduced binding to platelets.
-
Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.
-
Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding.
-
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
-
First report of the point-of-care TEG: A technical validation study of the TEG-6S system.
-
Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
-
Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets.
-
Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes.
-
Future alternatives to heparin: low-molecular-weight heparin and hirudin.
-
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.
-
Genome sequencing unveils a regulatory landscape of platelet reactivity.
-
Glutathione peroxidase-3 deficiency promotes platelet-dependent thrombosis in vivo.
-
Hemostatic changes after dietary coenzyme Q10 supplementation in swine.
-
Heparin-induced thrombocytopenia and thrombosis.
-
Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction.
-
High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?
-
High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype.
-
Hostility and platelet reactivity in individuals without a history of cardiovascular disease events.
-
Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.
-
Identification of alpha-adrenergic receptors in human platelets by [3H]dihydroergocryptine binding.
-
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
-
Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters.
-
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
-
Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account.
-
In vitro effects of acetaminophen and its analogues on human platelet aggregation and thromboxane B2 synthesis.
-
In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
-
Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis.
-
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.
-
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
-
Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes.
-
Infectious and bleeding complications in patients with glycogenosis Ib.
-
Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists.
-
Influence of Sex on Platelet Reactivity in Response to Aspirin.
-
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
-
Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients.
-
Inhibited and Uninhibited Platelet Deposition Within a Thrombus: Does It Depend on the Antiplatelet Drug?
-
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
-
Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction.
-
Inhibitors of platelet adhesion.
-
Inhibitory effect of ristocetin and factor VIII/von Willebrand factor protein on human platelet adenylate cyclase activity.
-
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
-
Insignificant blood damage in calves with a total artificial heart up to six months.
-
Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.
-
Interference of chylomicrons in analysis of platelets by flow cytometry.
-
Isn't it about time we learned how to use blood transfusion in patients with ischemic heart disease?
-
Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy.
-
Lack of thromboxane A2 synthesis in platelet aggregation induced by factor VIII/von Willebrand factor.
-
Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement".
-
Local administration of L-703,081 using a composite polymeric stent reduces platelet deposition in canine coronary arteries.
-
Mapping of a ligand-binding site for the human thromboxane A2 receptor protein.
-
Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices.
-
Membrane protein mediation of thromboxane A2-induced platelet aggregation.
-
Menorrhagia in patients with type I glycogen storage disease.
-
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
-
Mild myocardial stunning affects platelet aggregation and certain hemostatic factors in swine.
-
Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction.
-
Modulation of platelet shape and membrane receptor binding by Ca2+-calmodulin complex.
-
Molecular biology of chronic thromboembolic pulmonary hypertension.
-
Monitoring platelet inhibition during chronic oral platelet glycoprotein IIb/IIIa blockade: are we missing something?
-
Morning blood pressure surge, morning platelet aggregation, and silent cerebral infarction in older Japanese hypertensive patients.
-
Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
-
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
-
Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.
-
Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
-
Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events.
-
Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy.
-
Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention.
-
Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial.
-
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
-
Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study.
-
Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response.
-
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.
-
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
-
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
-
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
-
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.
-
Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
-
Platelet Function Testing Before CABG is Recommended in the Guidelines: But Do We Have Enough Evidence?
-
Platelet Reactivity and Coagulation Markers in Patients with COVID-19.
-
Platelet activation after stenting with heparin-coated versus noncoated stents.
-
Platelet activation and its patient-specific consequences.
-
Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease.
-
Platelet adhesion on a bioresorbable poly(propylene fumarate-co-ethylene glycol) copolymer.
-
Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.
-
Platelet function and fibrinolytic agents: two sides of a coin?
-
Platelet function and pharmacologic inhibition.
-
Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients.
-
Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y₁₂ inhibitor therapeutic window.
-
Platelet inhibition by low-dose aspirin is not influenced by body mass or weight.
-
Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors.
-
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
-
Platelet reactivity and thrombogenicity in postmenopausal women.
-
Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans.
-
Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.
-
Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.
-
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
-
Point-of-care platelet function analysis ready for prime time?
-
Prasugrel.
-
Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.
-
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
-
Preliminary observations on abnormalities of membrane structure and function in essential hypertension.
-
Pretreatment with an inhibitor of mac-1 alters regional and systemic platelet function during ischemia-reperfusion in swine.
-
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.
-
Procoagulant and platelet aggregating properties of antilymphocyte sera.
-
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
-
Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
-
Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
-
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
-
Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
-
Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
-
Relationship between age and platelet activation in patients with stable and unstable angina.
-
Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein.
-
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
-
Response variability and the role of platelet function testing.
-
Risk of heparin-induced thrombocytopenia from heparin-bonded vascular prostheses.
-
Role of prostacyclin in the cardiovascular response to thromboxane A2.
-
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty.
-
Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease?
-
Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
-
Soluble factor in normal tissues that stimulates high-molecular-weight sialoglycoprotein production by human colon carcinoma cells.
-
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
-
Statins do not affect platelet inhibition with clopidogrel during coronary stenting.
-
Substructure of human von Willebrand factor. Proteolysis by V8 and characterization of two functional domains.
-
The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin.
-
The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.
-
The biochemistry of haemostasis.
-
The bleeding diathesis in human glycogen storage disease type I: in vitro identification of a naturally occurring inhibitor of ristocetin-induced platelet aggregation.
-
The difference between clopidogrel responsiveness and posttreatment platelet reactivity.
-
The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition.
-
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
-
The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity.
-
The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration.
-
The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.
-
The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties.
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
-
The effects of magnesium sulfate on maternal and fetal platelet aggregation.
-
The effects of milrinone on platelets in patients undergoing cardiac surgery.
-
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
-
The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study.
-
The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
-
The influence of red wine or white wine intake on platelet function and viscoelastic property of blood in volunteers.
-
The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.
-
The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting.
-
The pathogenesis of vascular thrombosis and its impact in microvascular surgery.
-
The platelet-related effects of tenecteplase versus alteplase versus reteplase.
-
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.
-
The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy.
-
The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.
-
The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
-
The role of platelet receptors and adhesion molecules in coronary artery disease.
-
The role of the porcine von Willebrand factor: baboon platelet interactions in pulmonary xenotransplantation.
-
The roles of alpha IIb beta 3-mediated outside-in signal transduction, thromboxane A2, and adenosine diphosphate in collagen-induced platelet aggregation.
-
The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy.
-
The unique characteristics of COVID-19 coagulopathy.
-
The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.
-
Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis.
-
Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes.
-
Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia.
-
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
-
Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.
-
Toward a therapeutic window for antiplatelet therapy in the elderly.
-
Transient platelet aggregation as a mechanism of unstable angina. Aggressive treatment with coronary angioplasty.
-
Twenty-Four-Hour Cardiovascular Effects of Electronic Cigarettes Compared With Cigarette Smoking in Dual Users.
-
Tyrosine phosphorylation of the beta3 cytoplasmic domain mediates integrin-cytoskeletal interactions.
-
Ultrastructural studies of unstable angina in living man.
-
Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI.
-
Uniform platelet activation exists before coronary stent implantation despite aspirin therapy.
-
Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade.
-
Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.
-
Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor.
-
Vitamin E and total parenteral nutrition.
-
What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?
-
Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial).
-
eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation in vitro.
-
Keywords of People
-
Erickson, Harold Paul,
Professor Emeritus of Cell Biology,
Cell Biology
-
Esclamado, Ramon Mitra,
Professor Emeritus of Head and Neck Surgery & Communication Sciences,
Head and Neck Surgery & Communication Sciences
-
O'Connor, Christopher Michael,
Richard Sean Stack, M.D. Distinguished Professor,
Medicine, Clinical Pharmacology